Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation
Alexander Pedroza-Gonzalez, Kangling Xu, Te-Chia Wu, Caroline Aspord, Sasha Tindle, Florentina Marches, Michael Gallegos, Elizabeth C Burton, Daniel Savino, Toshiyuki Hori, Yuetsu Tanaka, Sandra Zurawski, Gerard Zurawski, Laura Bover, Yong-Jun Liu, Jacques Banchereau, A Karolina Palucka, Alexander Pedroza-Gonzalez, Kangling Xu, Te-Chia Wu, Caroline Aspord, Sasha Tindle, Florentina Marches, Michael Gallegos, Elizabeth C Burton, Daniel Savino, Toshiyuki Hori, Yuetsu Tanaka, Sandra Zurawski, Gerard Zurawski, Laura Bover, Yong-Jun Liu, Jacques Banchereau, A Karolina Palucka
Abstract
The human breast tumor microenvironment can display features of T helper type 2 (Th2) inflammation, and Th2 inflammation can promote tumor development. However, the molecular and cellular mechanisms contributing to Th2 inflammation in breast tumors remain unclear. Here, we show that human breast cancer cells produce thymic stromal lymphopoietin (TSLP). Breast tumor supernatants, in a TSLP-dependent manner, induce expression of OX40L on dendritic cells (DCs). OX40L(+) DCs are found in primary breast tumor infiltrates. OX40L(+) DCs drive development of inflammatory Th2 cells producing interleukin-13 and tumor necrosis factor in vitro. Antibodies neutralizing TSLP or OX40L inhibit breast tumor growth and interleukin-13 production in a xenograft model. Thus, breast cancer cell-derived TSLP contributes to the inflammatory Th2 microenvironment conducive to breast tumor development by inducing OX40L expression on DCs.
Figures
References
- Ali S.A., Ahmad M., Lynam J., McLean C.S., Entwisle C., Loudon P., Choolun E., McArdle S.E., Li G., Mian S., Rees R.C. 2004. Anti-tumour therapeutic efficacy of OX40L in murine tumour model. Vaccine. 22:3585–3594 10.1016/j.vaccine.2004.03.041
- Aspord C., Pedroza-Gonzalez A., Gallegos M., Tindle S., Burton E.C., Su D., Marches F., Banchereau J., Palucka A.K. 2007. Breast cancer instructs dendritic cells to prime interleukin 13–secreting CD4+ T cells that facilitate tumor development. J. Exp. Med. 204:1037–1047 10.1084/jem.20061120
- Bell D., Chomarat P., Broyles D., Netto G., Harb G.M., Lebecque S., Valladeau J., Davoust J., Palucka K.A., Banchereau J. 1999. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J. Exp. Med. 190:1417–1426 10.1084/jem.190.10.1417
- Berzofsky J.A., Terabe M. 2008. A novel immunoregulatory axis of NKT cell subsets regulating tumor immunity. Cancer Immunol. Immunother. 57:1679–1683 10.1007/s00262-008-0495-4
- Brimnes M.K., Bonifaz L., Steinman R.M., Moran T.M. 2003. Influenza virus–induced dendritic cell maturation is associated with the induction of strong T cell immunity to a coadministered, normally nonimmunogenic protein. J. Exp. Med. 198:133–144 10.1084/jem.20030266
- Camp J.T., Elloumi F., Roman-Perez E., Rein J., Stewart D.A., Harrell J.C., Perou C.M., Troester M.A. 2011. Interactions with fibroblasts are distinct in Basal-like and luminal breast cancers. Mol. Cancer Res. 9:3–13 10.1158/1541-7786.MCR-10-0372
- Caux C., Massacrier C., Vanbervliet B., Dubois B., Durand I., Cella M., Lanzavecchia A., Banchereau J. 1997. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha: II. Functional analysis. Blood. 90:1458–1470
- Condeelis J., Pollard J.W. 2006. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 124:263–266 10.1016/j.cell.2006.01.007
- Coughlin S.S., Ekwueme D.U. 2009. Breast cancer as a global health concern. Cancer Epidemiol. 33:315–318 10.1016/j.canep.2009.10.003
- Coussens L.M., Werb Z. 2002. Inflammation and cancer. Nature. 420:860–867 10.1038/nature01322
- Croft M., So T., Duan W., Soroosh P. 2009. The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol. Rev. 229:173–191 10.1111/j.1600-065X.2009.00766.x
- DeNardo D.G., Barreto J.B., Andreu P., Vasquez L., Tawfik D., Kolhatkar N., Coussens L.M. 2009. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell. 16:91–102 10.1016/j.ccr.2009.06.018
- Dudziak D., Kamphorst A.O., Heidkamp G.F., Buchholz V.R., Trumpfheller C., Yamazaki S., Cheong C., Liu K., Lee H.W., Park C.G., et al. 2007. Differential antigen processing by dendritic cell subsets in vivo. Science. 315:107–111 10.1126/science.1136080
- Finkelman F.D., Lees A., Birnbaum R., Gause W.C., Morris S.C. 1996. Dendritic cells can present antigen in vivo in a tolerogenic or immunogenic fashion. J. Immunol. 157:1406–1414
- Gilliet M., Soumelis V., Watanabe N., Hanabuchi S., Antonenko S., de Waal-Malefyt R., Liu Y.J. 2003. Human dendritic cells activated by TSLP and CD40L induce proallergic cytotoxic T cells. J. Exp. Med. 197:1059–1063 10.1084/jem.20030240
- Gobert M., Treilleux I., Bendriss-Vermare N., Bachelot T., Goddard-Leon S., Arfi V., Biota C., Doffin A.C., Durand I., Olive D., et al. 2009. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 69:2000–2009 10.1158/0008-5472.CAN-08-2360
- Grivennikov S.I., Greten F.R., Karin M. 2010. Immunity, inflammation, and cancer. Cell. 140:883–899 10.1016/j.cell.2010.01.025
- Hackett A.J., Smith H.S., Springer E.L., Owens R.B., Nelson-Rees W.A., Riggs J.L., Gardner M.B. 1977. Two syngeneic cell lines from human breast tissue: the aneuploid mammary epithelial (Hs578T) and the diploid myoepithelial (Hs578Bst) cell lines. J. Natl. Cancer Inst. 58:1795–1806
- Hawiger D., Inaba K., Dorsett Y., Guo M., Mahnke K., Rivera M., Ravetch J.V., Steinman R.M., Nussenzweig M.C. 2001. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194:769–779 10.1084/jem.194.6.769
- Heibein J.A., Goping I.S., Barry M., Pinkoski M.J., Shore G.C., Green D.R., Bleackley R.C. 2000. Granzyme B-mediated cytochrome c release is regulated by the Bcl-2 family members bid and Bax. J. Exp. Med. 192:1391–1402 10.1084/jem.192.10.1391
- Iorio M.V., Ferracin M., Liu C.G., Veronese A., Spizzo R., Sabbioni S., Magri E., Pedriali M., Fabbri M., Campiglio M., et al. 2005. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65:7065–7070 10.1158/0008-5472.CAN-05-1783
- Ito T., Wang Y.H., Duramad O., Hori T., Delespesse G.J., Watanabe N., Qin F.X., Yao Z., Cao W., Liu Y.J. 2005. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J. Exp. Med. 202:1213–1223 10.1084/jem.20051135
- Kapp U., Yeh W.C., Patterson B., Elia A.J., Kägi D., Ho A., Hessel A., Tipsword M., Williams A., Mirtsos C., et al. 1999. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J. Exp. Med. 189:1939–1946 10.1084/jem.189.12.1939
- Khaled W.T., Read E.K., Nicholson S.E., Baxter F.O., Brennan A.J., Came P.J., Sprigg N., McKenzie A.N., Watson C.J. 2007. The IL-4/IL-13/Stat6 signalling pathway promotes luminal mammary epithelial cell development. Development. 134:2739–2750 10.1242/dev.003194
- Klechevsky E., Morita R., Liu M., Cao Y., Coquery S., Thompson-Snipes L., Briere F., Chaussabel D., Zurawski G., Palucka A.K., et al. 2008. Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity. 29:497–510 10.1016/j.immuni.2008.07.013
- Lacroix M., Leclercq G. 2004. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res. Treat. 83:249–289 10.1023/B:
- Levings M.K., Gregori S., Tresoldi E., Cazzaniga S., Bonini C., Roncarolo M.G. 2005. Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. Blood. 105:1162–1169 10.1182/blood-2004-03-1211
- Liu Y.J., Soumelis V., Watanabe N., Ito T., Wang Y.H., Malefyt Rde.W., Omori M., Zhou B., Ziegler S.F. 2007a. TSLP: an epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation. Annu. Rev. Immunol. 25:193–219 10.1146/annurev.immunol.25.022106.141718
- Luft T., Jefford M., Luetjens P., Toy T., Hochrein H., Masterman K.A., Maliszewski C., Shortman K., Cebon J., Maraskovsky E. 2002. Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets. Blood. 100:1362–1372 10.1182/blood-2001-12-0360
- Maldonado-López R., De Smedt T., Michel P., Godfroid J., Pajak B., Heirman C., Thielemans K., Leo O., Urbain J., Moser M. 1999. CD8alpha+ and CD8alpha- subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J. Exp. Med. 189:587–592 10.1084/jem.189.3.587
- Mantovani A., Sica A. 2010. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr. Opin. Immunol. 22:231–237 10.1016/j.coi.2010.01.009
- Mantovani A., Romero P., Palucka A.K., Marincola F.M. 2008. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet. 371:771–783 10.1016/S0140-6736(08)60241-X
- Morris A., Vetto J.T., Ramstad T., Funatake C.J., Choolun E., Entwisle C., Weinberg A.D. 2001. Induction of anti-mammary cancer immunity by engaging the OX-40 receptor in vivo. Breast Cancer Res. Treat. 67:71–80 10.1023/A:1010649303056
- Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., Clark L., Bayani N., Coppe J.P., Tong F., et al. 2006. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 10:515–527 10.1016/j.ccr.2006.10.008
- Park J.M., Terabe M., van den Broeke L.T., Donaldson D.D., Berzofsky J.A. 2005. Unmasking immunosurveillance against a syngeneic colon cancer by elimination of CD4+ NKT regulatory cells and IL-13. Int. J. Cancer. 114:80–87 10.1002/ijc.20669
- Park J.M., Terabe M., Donaldson D.D., Forni G., Berzofsky J.A. 2008. Natural immunosurveillance against spontaneous, autochthonous breast cancers revealed and enhanced by blockade of IL-13-mediated negative regulation. Cancer Immunol. Immunother. 57:907–912 10.1007/s00262-007-0414-0
- Piconese S., Valzasina B., Colombo M.P. 2008. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J. Exp. Med. 205:825–839 10.1084/jem.20071341
- Pulendran B., Smith J.L., Caspary G., Brasel K., Pettit D., Maraskovsky E., Maliszewski C.R. 1999. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc. Natl. Acad. Sci. USA. 96:1036–1041 10.1073/pnas.96.3.1036
- Rakoff-Nahoum S., Medzhitov R. 2009. Toll-like receptors and cancer. Nat. Rev. Cancer. 9:57–63 10.1038/nrc2541
- Sarin A., Williams M.S., Alexander-Miller M.A., Berzofsky J.A., Zacharchuk C.M., Henkart P.A. 1997. Target cell lysis by CTL granule exocytosis is independent of ICE/Ced-3 family proteases. Immunity. 6:209–215 10.1016/S1074-7613(00)80427-6
- Shimamura T., Fujisawa T., Husain S.R., Joshi B., Puri R.K. 2010. Interleukin 13 mediates signal transduction through interleukin 13 receptor alpha2 in pancreatic ductal adenocarcinoma: role of IL-13 Pseudomonas exotoxin in pancreatic cancer therapy. Clin. Cancer Res. 16:577–586 10.1158/1078-0432.CCR-09-2015
- Skinnider B.F., Elia A.J., Gascoyne R.D., Trümper L.H., von Bonin F., Kapp U., Patterson B., Snow B.E., Mak T.W. 2001. Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 97:250–255 10.1182/blood.V97.1.250
- Skinnider B.F., Elia A.J., Gascoyne R.D., Patterson B., Trumper L., Kapp U., Mak T.W. 2002. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 99:618–626 10.1182/blood.V99.2.618
- Smirnov D.A., Cheung V.G. 2008. ATM gene mutations result in both recessive and dominant expression phenotypes of genes and microRNAs. Am. J. Hum. Genet. 83:243–253 10.1016/j.ajhg.2008.07.003
- Soule H.D., Vazguez J., Long A., Albert S., Brennan M. 1973. A human cell line from a pleural effusion derived from a breast carcinoma. J. Natl. Cancer Inst. 51:1409–1416
- Soumelis V., Reche P.A., Kanzler H., Yuan W., Edward G., Homey B., Gilliet M., Ho S., Antonenko S., Lauerma A., et al. 2002. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat. Immunol. 3:673–680
- Steinbrink K., Jonuleit H., Müller G., Schuler G., Knop J., Enk A.H. 1999. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. Blood. 93:1634–1642
- Steinman R.M., Banchereau J. 2007. Taking dendritic cells into medicine. Nature. 449:419–426 10.1038/nature06175
- Steinman R.M., Hawiger D., Nussenzweig M.C. 2003. Tolerogenic dendritic cells. Annu. Rev. Immunol. 21:685–711 10.1146/annurev.immunol.21.120601.141040
- Swift M., Reitnauer P.J., Morrell D., Chase C.L. 1987. Breast and other cancers in families with ataxia-telangiectasia. N. Engl. J. Med. 316:1289–1294 10.1056/NEJM198705213162101
- Terabe M., Matsui S., Noben-Trauth N., Chen H., Watson C., Donaldson D.D., Carbone D.P., Paul W.E., Berzofsky J.A. 2000. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat. Immunol. 1:515–520 10.1038/82771
- Terabe M., Matsui S., Park J.M., Mamura M., Noben-Trauth N., Donaldson D.D., Chen W., Wahl S.M., Ledbetter S., Pratt B., et al. 2003. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J. Exp. Med. 198:1741–1752 10.1084/jem.20022227
- Todaro M., Lombardo Y., Francipane M.G., Alea M.P., Cammareri P., Iovino F., Di Stefano A.B., Di Bernardo C., Agrusa A., Condorelli G., et al. 2008. Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4. Cell Death Differ. 15:762–772 10.1038/sj.cdd.4402305
- Trieu Y., Wen X.Y., Skinnider B.F., Bray M.R., Li Z., Claudio J.O., Masih-Khan E., Zhu Y.X., Trudel S., McCart J.A., et al. 2004. Soluble interleukin-13Ralpha2 decoy receptor inhibits Hodgkin’s lymphoma growth in vitro and in vivo. Cancer Res. 64:3271–3275 10.1158/0008-5472.CAN-03-3764
- Villablanca E.J., Raccosta L., Zhou D., Fontana R., Maggioni D., Negro A., Sanvito F., Ponzoni M., Valentinis B., Bregni M., et al. 2010. Tumor-mediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses. Nat. Med. 16:98–105 10.1038/nm.2074
- Watanabe N., Hanabuchi S., Marloie-Provost M.A., Antonenko S., Liu Y.J., Soumelis V. 2005a. Human TSLP promotes CD40 ligand-induced IL-12 production by myeloid dendritic cells but maintains their Th2 priming potential. Blood. 105:4749–4751 10.1182/blood-2004-09-3622
- Watanabe N., Wang Y.H., Lee H.K., Ito T., Wang Y.H., Cao W., Liu Y.J. 2005b. Hassall’s corpuscles instruct dendritic cells to induce CD4+CD25+ regulatory T cells in human thymus. Nature. 436:1181–1185 10.1038/nature03886
- Weinberg A.D., Rivera M.M., Prell R., Morris A., Ramstad T., Vetto J.T., Urba W.J., Alvord G., Bunce C., Shields J. 2000. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J. Immunol. 164:2160–2169
- Xie F., Wang Q., Chen Y., Gu Y., Mao H., Zeng W., Zhang X. 2010. Costimulatory molecule OX40/OX40L expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study. Pathol. Res. Pract. 206:735–739 10.1016/j.prp.2010.05.016
- Zhang W.J., Li B.H., Yang X.Z., Li P.D., Yuan Q., Liu X.H., Xu S.B., Zhang Y., Yuan J., Gerhard G.S., et al. 2008. IL-4-induced Stat6 activities affect apoptosis and gene expression in breast cancer cells. Cytokine. 42:39–47 10.1016/j.cyto.2008.01.016
- Ziegler S.F., Artis D. 2010. Sensing the outside world: TSLP regulates barrier immunity. Nat. Immunol. 11:289–293 10.1038/ni.1852
Source: PubMed